
Mitigation and Prevention
The article highlights the lessons learned from the COVID-19 pandemic and their influence on preparations for future public health emergencies. While the federal Public Health Emergency for COVID-19 is set to end in May 2023, the FDA emphasizes the continued importance of COVID-19 vaccines and treatments. Addressing misinformation and strengthening supply chain resilience are key priorities, and the FDA is developing more efficient inspection planning systems. Modernizing FDA authorities and maintaining a commitment to planning for the future are also emphasized to enhance national security and public health preparedness.